SION
Sionna Therapeutics, Inc.
$44.23
+2.12%
2026-05-08
About Sionna Therapeutics, Inc.
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
Key Fundamentals
Forward P/E
-17.47
EPS (TTM)
$-1.88
ROE
-31.8%
Profit Margin
0.0%
Debt/Equity
2.83
Price/Book
6.43
Market Cap
$1.99B
Avg Volume (10D)
407K
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$46.46
60D Low
$32.56
Avg Volume
344K
Latest Close
$44.23
Get breakout alerts for SION
Sign up for Breakout Scanner to receive daily notifications when SION triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
Sionna Therapeutics, Inc. (SION) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors SION daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. SION operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.